Atlas Trials

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

Clinical trial NCT02157506 · COMPLETED

Trial details

NCT number
NCT02157506
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Heart FailureDecompensated Heart FailureAcute Heart Failure
Start date
2014-06-30
Primary completion
2015-05-31
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.